Zafgen: 3 Key Takeaways From ADA Abstracts

Zafgen (ZFGN) released three abstracts at the American Diabetes Association conference. Amongst them included full results in a phase 2 proof-of-concept trial assessing ZGN-1061 in uncontrolled type 2 diabetes mellitus. The trial is still ongoing, as a higher dose was added later on in light of positive safety. We will review the results of the "core" trial.

ZGN-1061 is effective in reducing hemoglobin A1C and will likely be of greater efficacy with higher doses

As predicted, 1061 proved to be safe and effective in reducing Hgb A1C. This secured one of the milestones I proposed would be necessary for shares of Zafgen to be trading at $15:

READ FULL ARTICLE HERE